Esther Rajavelu

CIK: 0001903716

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)8 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SPRO

Spero Therapeutics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (12 total)

SPRO
Spero Therapeutics, Inc.
May 4, 2026
Sale(S)
Direct
25.2K shares at avg. $2.51$63K
SPRO
Spero Therapeutics, Inc.
Feb 6, 2026
Sale(S)
Direct
37.1K shares at avg. $2.36$88K
SPRO
Spero Therapeutics, Inc.
Feb 6, 2026
Sale(S)
Direct
50.8K shares at avg. $2.36$120K
SPRO
Spero Therapeutics, Inc.
Feb 2, 2026
Sale(S)
Direct
18.4K shares at avg. $2.20$41K
SPRO
Spero Therapeutics, Inc.
Feb 2, 2026
Award(A)
Direct
249K shares-
SPRO
Spero Therapeutics, Inc.
Nov 7, 2025
Sale(S)
Direct
40.3K shares at avg. $2.37$95K
SPRO
Spero Therapeutics, Inc.
May 2, 2025
Award(A)
Direct
185K shares-
SPRO
Spero Therapeutics, Inc.
Feb 5, 2025
Sale(S)
Direct
20.7K shares at avg. $0.78$16K
SPRO
Spero Therapeutics, Inc.
Feb 3, 2025
Award(A)
Direct
266.1K shares-
SPRO
Spero Therapeutics, Inc.
Feb 3, 2025
Award(A)
Direct
100K shares-
SPRO
Spero Therapeutics, Inc.
Nov 8, 2024
Sale(S)
Direct
17.2K shares at avg. $1.30$22K
SPRO
Spero Therapeutics, Inc.
Nov 7, 2024
Sale(S)
Direct
23.4K shares at avg. $1.31$31K

		Type	Shares	Price		Ownership
May 4, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	25,240	$2.51	$63,352	Direct
Feb 6, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	37,101	$2.36	$87,558	Direct
Feb 6, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	50,816	$2.36	$119,926	Direct
Feb 2, 2026	SPRO Spero Therapeutics, Inc.	Sale(S)	18,442	$2.20	$40,572	Direct
Feb 2, 2026	SPRO Spero Therapeutics, Inc.	Award(A)	249,000	-	$0	Direct
Nov 7, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	40,270	$2.37	$95,440	Direct
May 2, 2025	SPRO Spero Therapeutics, Inc.	Award(A)	185,000	-	-	Direct
Feb 5, 2025	SPRO Spero Therapeutics, Inc.	Sale(S)	20,689	$0.78	$16,137	Direct
Feb 3, 2025	SPRO Spero Therapeutics, Inc.	Award(A)	266,139	-	-	Direct
Feb 3, 2025	SPRO Spero Therapeutics, Inc.	Award(A)	100,000	-	-	Direct
Nov 8, 2024	SPRO Spero Therapeutics, Inc.	Sale(S)	17,245	$1.30	$22,419	Direct
Nov 7, 2024	SPRO Spero Therapeutics, Inc.	Sale(S)	23,351	$1.31	$30,590	Direct

1-12 of 12 transactions

About Rajavelu Esther

Rajavelu Esther (SEC CIK 0001903716) files insider reports with the SEC as Officer of Spero Therapeutics, Inc. (SPRO).

Signal8 holds 7 ownership filings by Rajavelu Esther, all Form 4s, filed between Nov 12, 2024 and May 6, 2026. Those filings report 12 transactions, from Nov 7, 2024 to May 4, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Rajavelu Esther's filings is in CAMBRIDGE, MA.

Recent filings by Rajavelu Esther

May 4, 2026: Open-market sale of SPRO shares (Form 4, code S).
Feb 6, 2026: Open-market sales of SPRO shares (2 lines, Form 4, code S).
Feb 2, 2026: Open-market sale of SPRO shares (Form 4, code S).
Feb 2, 2026: Grant or award of SPRO shares (Form 4, code A).
Nov 7, 2025: Open-market sale of SPRO shares (Form 4, code S).

Other insiders filing for Spero Therapeutics, Inc. (SPRO)

Zack Debra, Chief Medical Officer
Deshpande Milind, Director
Tregoning Kathleen, Director
Smith Cynthia, Director
VINK PATRICK V.J.J., Director
THOMAS FRANK E, Director

How to read Form 4 transaction codes